Approximately 6600 patients from North America and Europe.
Primary outcome is progression of clinical coronary artery disease.
Approximately 2200 patients with congestive heart failure randomized to receive optimal drug treatment vs optimal drug treatment with biventricular pacing vs optimal drug treatment with biventricular pacing and defibrillation. Approximately 840 patients in two trials in North America and Europe. Primary endpoint is progression of retinopathy. Primary endpoint was all-cause mortality. Results will be presented at the August 2000 European College of Cardiology meetings.